P86 Hepatitis C virusmicro elimination in Sussex: interim results from the END C study
IntroductionAs we approach the final stages of Hepatitis C virus (HCV) elimination, we are left with increasingly more complex individuals to treat. Based on our initial novel “one stop” community HCV care model in Brighton focussed at people who use drugs (ITTREAT) and people who are homeless, we s...
Gespeichert in:
Veröffentlicht in: | Gut 2022-06, Vol.71 (Suppl 1), p.A81-A81 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A81 |
---|---|
container_issue | Suppl 1 |
container_start_page | A81 |
container_title | Gut |
container_volume | 71 |
creator | Mourad, Adele McGeer, Rona Gray, Emma Salvaggio, Lidia Jones, Anna-Marie O’Sullivan, Margaret Gage, Heather Verma, Sumita |
description | IntroductionAs we approach the final stages of Hepatitis C virus (HCV) elimination, we are left with increasingly more complex individuals to treat. Based on our initial novel “one stop” community HCV care model in Brighton focussed at people who use drugs (ITTREAT) and people who are homeless, we set up the END C study to achieve HCV micro elimination across Sussex.MethodsEND C Study (2019-2023) is based at multiple homeless sites across Sussex. We provide an integrated service that includes blood borne virus (BBV) testing (point of care HCV RNA testing), assessment of alcohol/drug use/liver fibrosis and HCV treatment. We are using innovative strategies to encourage linkage to care. Primary outcome measure is sustained virological response SVR12 (intention to treat [ITT]). Secondary outcomes include health related quality of life (HRQoL), Short Form Liver Disease Quality of Life (SFLDQoL), Short Form Health Survey (SF-12v2), and EQ-5D-5L, assessed at end in those achieving SVR12; cost per HCV case detected and cost per HCV cure. All data are prospectively collected.ResultsTo date, 336 individuals have been recruited, 79% being male with a mean age of 44.5 ± 10.8 years. Around three-fifths (62%) were currently drinking alcohol, 25% were currently injecting drugs, 30% were on opioid agonist treatment and 259 (82%) individuals were currently homeless with 58 (18%) currently housed. Comparing currently homeless vs currently housed data as follows: age (years) 44.2 ± 10.8 years vs. 45.8 ± 10.6 (p=0.3070), current drinking 58% vs. 81% (p=0.0012), current IDU 26% vs. 21% (p=0.4303), HCV PCR positivity 23% vs. 34% (p=0.0805) respectively. Uptake of transient elastography was 77% with 45% having ≥ F2 fibrosis (LSM>7.1kPa) and 25% having cirrhosis (LSM>12kPa). Overall, prevalence of positive HCV PCR was 26% (n=86). of those with a positive PCR, 69% (n=59) have commenced HCV treatment thus far. of those commencing HCV treatment 39 people have completed treatment with an SVR12 being 85%. Patient reported outcome and health economic data is on-going.ConclusionInterim results from END C study confirm the easy reproducibility of our earlier community model. Despite being a vulnerable and disenfranchised cohort, early END C data shows excellent service uptake and SVR12 results.References Hashim et al. Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. Liver Int. 2021;1– 12 . O’Sullivanet al. ITTRE |
doi_str_mv | 10.1136/gutjnl-2022-BSG.143 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2711573292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2711573292</sourcerecordid><originalsourceid>FETCH-LOGICAL-b682-cf82d002233a0cb658a5ee32a4e2f96e662087559c6cf3283f4ecb4166bb6cf3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EEqXwBWwssXbrR-I47KCUFqkCpLJgZyXpBBzlUfxAsGPDj_IluCoSqxnNXN25cxA6Z3TCmJDTl-CbviWcck6u14sJS8QBGrFEKiK4UodoRCnLSJol-TE6ca6hlCqVsxF6flTy5-t7CdvCG28cnuF3Y4PrTGUHDK3pTB83Q49Nj9fBOfi4jK0HazpswYXWO1zbocP-FfD8_iYaOB82n6foqC5aB2d_dYzWt_On2ZKsHhZ3s6sVKaXipKoV39AYW4iCVqVMVZECCF4kwOtcgpScqixN80pWdXxF1AlUZcKkLMvdZIwu9q5bO7wFcF43Q7B9PKh5xliaCZ7zqJruVWXX_AsY1Tt4eg9P7-DpCE9HeOIXrnhkww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2711573292</pqid></control><display><type>article</type><title>P86 Hepatitis C virusmicro elimination in Sussex: interim results from the END C study</title><source>PubMed Central</source><creator>Mourad, Adele ; McGeer, Rona ; Gray, Emma ; Salvaggio, Lidia ; Jones, Anna-Marie ; O’Sullivan, Margaret ; Gage, Heather ; Verma, Sumita</creator><creatorcontrib>Mourad, Adele ; McGeer, Rona ; Gray, Emma ; Salvaggio, Lidia ; Jones, Anna-Marie ; O’Sullivan, Margaret ; Gage, Heather ; Verma, Sumita</creatorcontrib><description>IntroductionAs we approach the final stages of Hepatitis C virus (HCV) elimination, we are left with increasingly more complex individuals to treat. Based on our initial novel “one stop” community HCV care model in Brighton focussed at people who use drugs (ITTREAT) and people who are homeless, we set up the END C study to achieve HCV micro elimination across Sussex.MethodsEND C Study (2019-2023) is based at multiple homeless sites across Sussex. We provide an integrated service that includes blood borne virus (BBV) testing (point of care HCV RNA testing), assessment of alcohol/drug use/liver fibrosis and HCV treatment. We are using innovative strategies to encourage linkage to care. Primary outcome measure is sustained virological response SVR12 (intention to treat [ITT]). Secondary outcomes include health related quality of life (HRQoL), Short Form Liver Disease Quality of Life (SFLDQoL), Short Form Health Survey (SF-12v2), and EQ-5D-5L, assessed at end in those achieving SVR12; cost per HCV case detected and cost per HCV cure. All data are prospectively collected.ResultsTo date, 336 individuals have been recruited, 79% being male with a mean age of 44.5 ± 10.8 years. Around three-fifths (62%) were currently drinking alcohol, 25% were currently injecting drugs, 30% were on opioid agonist treatment and 259 (82%) individuals were currently homeless with 58 (18%) currently housed. Comparing currently homeless vs currently housed data as follows: age (years) 44.2 ± 10.8 years vs. 45.8 ± 10.6 (p=0.3070), current drinking 58% vs. 81% (p=0.0012), current IDU 26% vs. 21% (p=0.4303), HCV PCR positivity 23% vs. 34% (p=0.0805) respectively. Uptake of transient elastography was 77% with 45% having ≥ F2 fibrosis (LSM>7.1kPa) and 25% having cirrhosis (LSM>12kPa). Overall, prevalence of positive HCV PCR was 26% (n=86). of those with a positive PCR, 69% (n=59) have commenced HCV treatment thus far. of those commencing HCV treatment 39 people have completed treatment with an SVR12 being 85%. Patient reported outcome and health economic data is on-going.ConclusionInterim results from END C study confirm the easy reproducibility of our earlier community model. Despite being a vulnerable and disenfranchised cohort, early END C data shows excellent service uptake and SVR12 results.References Hashim et al. Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. Liver Int. 2021;1– 12 . O’Sullivanet al. ITTREAT Hepatitis C service for people who use drugs: Real-world outcomes. Liver Int. 2020; 40: 1021– 1031.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gutjnl-2022-BSG.143</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject>Cirrhosis ; Drinking behavior ; Fibrosis ; Hepatitis C ; Homeless people ; Liver cirrhosis ; Liver diseases ; Poster presentations ; Quality of life</subject><ispartof>Gut, 2022-06, Vol.71 (Suppl 1), p.A81-A81</ispartof><rights>Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2022 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Mourad, Adele</creatorcontrib><creatorcontrib>McGeer, Rona</creatorcontrib><creatorcontrib>Gray, Emma</creatorcontrib><creatorcontrib>Salvaggio, Lidia</creatorcontrib><creatorcontrib>Jones, Anna-Marie</creatorcontrib><creatorcontrib>O’Sullivan, Margaret</creatorcontrib><creatorcontrib>Gage, Heather</creatorcontrib><creatorcontrib>Verma, Sumita</creatorcontrib><title>P86 Hepatitis C virusmicro elimination in Sussex: interim results from the END C study</title><title>Gut</title><addtitle>Gut</addtitle><description>IntroductionAs we approach the final stages of Hepatitis C virus (HCV) elimination, we are left with increasingly more complex individuals to treat. Based on our initial novel “one stop” community HCV care model in Brighton focussed at people who use drugs (ITTREAT) and people who are homeless, we set up the END C study to achieve HCV micro elimination across Sussex.MethodsEND C Study (2019-2023) is based at multiple homeless sites across Sussex. We provide an integrated service that includes blood borne virus (BBV) testing (point of care HCV RNA testing), assessment of alcohol/drug use/liver fibrosis and HCV treatment. We are using innovative strategies to encourage linkage to care. Primary outcome measure is sustained virological response SVR12 (intention to treat [ITT]). Secondary outcomes include health related quality of life (HRQoL), Short Form Liver Disease Quality of Life (SFLDQoL), Short Form Health Survey (SF-12v2), and EQ-5D-5L, assessed at end in those achieving SVR12; cost per HCV case detected and cost per HCV cure. All data are prospectively collected.ResultsTo date, 336 individuals have been recruited, 79% being male with a mean age of 44.5 ± 10.8 years. Around three-fifths (62%) were currently drinking alcohol, 25% were currently injecting drugs, 30% were on opioid agonist treatment and 259 (82%) individuals were currently homeless with 58 (18%) currently housed. Comparing currently homeless vs currently housed data as follows: age (years) 44.2 ± 10.8 years vs. 45.8 ± 10.6 (p=0.3070), current drinking 58% vs. 81% (p=0.0012), current IDU 26% vs. 21% (p=0.4303), HCV PCR positivity 23% vs. 34% (p=0.0805) respectively. Uptake of transient elastography was 77% with 45% having ≥ F2 fibrosis (LSM>7.1kPa) and 25% having cirrhosis (LSM>12kPa). Overall, prevalence of positive HCV PCR was 26% (n=86). of those with a positive PCR, 69% (n=59) have commenced HCV treatment thus far. of those commencing HCV treatment 39 people have completed treatment with an SVR12 being 85%. Patient reported outcome and health economic data is on-going.ConclusionInterim results from END C study confirm the easy reproducibility of our earlier community model. Despite being a vulnerable and disenfranchised cohort, early END C data shows excellent service uptake and SVR12 results.References Hashim et al. Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. Liver Int. 2021;1– 12 . O’Sullivanet al. ITTREAT Hepatitis C service for people who use drugs: Real-world outcomes. Liver Int. 2020; 40: 1021– 1031.</description><subject>Cirrhosis</subject><subject>Drinking behavior</subject><subject>Fibrosis</subject><subject>Hepatitis C</subject><subject>Homeless people</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Poster presentations</subject><subject>Quality of life</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpFkMtOwzAQRS0EEqXwBWwssXbrR-I47KCUFqkCpLJgZyXpBBzlUfxAsGPDj_IluCoSqxnNXN25cxA6Z3TCmJDTl-CbviWcck6u14sJS8QBGrFEKiK4UodoRCnLSJol-TE6ca6hlCqVsxF6flTy5-t7CdvCG28cnuF3Y4PrTGUHDK3pTB83Q49Nj9fBOfi4jK0HazpswYXWO1zbocP-FfD8_iYaOB82n6foqC5aB2d_dYzWt_On2ZKsHhZ3s6sVKaXipKoV39AYW4iCVqVMVZECCF4kwOtcgpScqixN80pWdXxF1AlUZcKkLMvdZIwu9q5bO7wFcF43Q7B9PKh5xliaCZ7zqJruVWXX_AsY1Tt4eg9P7-DpCE9HeOIXrnhkww</recordid><startdate>20220619</startdate><enddate>20220619</enddate><creator>Mourad, Adele</creator><creator>McGeer, Rona</creator><creator>Gray, Emma</creator><creator>Salvaggio, Lidia</creator><creator>Jones, Anna-Marie</creator><creator>O’Sullivan, Margaret</creator><creator>Gage, Heather</creator><creator>Verma, Sumita</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20220619</creationdate><title>P86 Hepatitis C virusmicro elimination in Sussex: interim results from the END C study</title><author>Mourad, Adele ; McGeer, Rona ; Gray, Emma ; Salvaggio, Lidia ; Jones, Anna-Marie ; O’Sullivan, Margaret ; Gage, Heather ; Verma, Sumita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b682-cf82d002233a0cb658a5ee32a4e2f96e662087559c6cf3283f4ecb4166bb6cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cirrhosis</topic><topic>Drinking behavior</topic><topic>Fibrosis</topic><topic>Hepatitis C</topic><topic>Homeless people</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Poster presentations</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mourad, Adele</creatorcontrib><creatorcontrib>McGeer, Rona</creatorcontrib><creatorcontrib>Gray, Emma</creatorcontrib><creatorcontrib>Salvaggio, Lidia</creatorcontrib><creatorcontrib>Jones, Anna-Marie</creatorcontrib><creatorcontrib>O’Sullivan, Margaret</creatorcontrib><creatorcontrib>Gage, Heather</creatorcontrib><creatorcontrib>Verma, Sumita</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mourad, Adele</au><au>McGeer, Rona</au><au>Gray, Emma</au><au>Salvaggio, Lidia</au><au>Jones, Anna-Marie</au><au>O’Sullivan, Margaret</au><au>Gage, Heather</au><au>Verma, Sumita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P86 Hepatitis C virusmicro elimination in Sussex: interim results from the END C study</atitle><jtitle>Gut</jtitle><stitle>Gut</stitle><date>2022-06-19</date><risdate>2022</risdate><volume>71</volume><issue>Suppl 1</issue><spage>A81</spage><epage>A81</epage><pages>A81-A81</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><abstract>IntroductionAs we approach the final stages of Hepatitis C virus (HCV) elimination, we are left with increasingly more complex individuals to treat. Based on our initial novel “one stop” community HCV care model in Brighton focussed at people who use drugs (ITTREAT) and people who are homeless, we set up the END C study to achieve HCV micro elimination across Sussex.MethodsEND C Study (2019-2023) is based at multiple homeless sites across Sussex. We provide an integrated service that includes blood borne virus (BBV) testing (point of care HCV RNA testing), assessment of alcohol/drug use/liver fibrosis and HCV treatment. We are using innovative strategies to encourage linkage to care. Primary outcome measure is sustained virological response SVR12 (intention to treat [ITT]). Secondary outcomes include health related quality of life (HRQoL), Short Form Liver Disease Quality of Life (SFLDQoL), Short Form Health Survey (SF-12v2), and EQ-5D-5L, assessed at end in those achieving SVR12; cost per HCV case detected and cost per HCV cure. All data are prospectively collected.ResultsTo date, 336 individuals have been recruited, 79% being male with a mean age of 44.5 ± 10.8 years. Around three-fifths (62%) were currently drinking alcohol, 25% were currently injecting drugs, 30% were on opioid agonist treatment and 259 (82%) individuals were currently homeless with 58 (18%) currently housed. Comparing currently homeless vs currently housed data as follows: age (years) 44.2 ± 10.8 years vs. 45.8 ± 10.6 (p=0.3070), current drinking 58% vs. 81% (p=0.0012), current IDU 26% vs. 21% (p=0.4303), HCV PCR positivity 23% vs. 34% (p=0.0805) respectively. Uptake of transient elastography was 77% with 45% having ≥ F2 fibrosis (LSM>7.1kPa) and 25% having cirrhosis (LSM>12kPa). Overall, prevalence of positive HCV PCR was 26% (n=86). of those with a positive PCR, 69% (n=59) have commenced HCV treatment thus far. of those commencing HCV treatment 39 people have completed treatment with an SVR12 being 85%. Patient reported outcome and health economic data is on-going.ConclusionInterim results from END C study confirm the easy reproducibility of our earlier community model. Despite being a vulnerable and disenfranchised cohort, early END C data shows excellent service uptake and SVR12 results.References Hashim et al. Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. Liver Int. 2021;1– 12 . O’Sullivanet al. ITTREAT Hepatitis C service for people who use drugs: Real-world outcomes. Liver Int. 2020; 40: 1021– 1031.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><doi>10.1136/gutjnl-2022-BSG.143</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0017-5749 |
ispartof | Gut, 2022-06, Vol.71 (Suppl 1), p.A81-A81 |
issn | 0017-5749 1468-3288 |
language | eng |
recordid | cdi_proquest_journals_2711573292 |
source | PubMed Central |
subjects | Cirrhosis Drinking behavior Fibrosis Hepatitis C Homeless people Liver cirrhosis Liver diseases Poster presentations Quality of life |
title | P86 Hepatitis C virusmicro elimination in Sussex: interim results from the END C study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A20%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P86%E2%80%85Hepatitis%20C%20virusmicro%20elimination%20in%20Sussex:%20interim%20results%20from%20the%20END%20C%20study&rft.jtitle=Gut&rft.au=Mourad,%20Adele&rft.date=2022-06-19&rft.volume=71&rft.issue=Suppl%201&rft.spage=A81&rft.epage=A81&rft.pages=A81-A81&rft.issn=0017-5749&rft.eissn=1468-3288&rft_id=info:doi/10.1136/gutjnl-2022-BSG.143&rft_dat=%3Cproquest_bmj_j%3E2711573292%3C/proquest_bmj_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2711573292&rft_id=info:pmid/&rfr_iscdi=true |